ACR on Air

This episode explores the evolving intersection of rheumatology and cognitive science, beginning with what initially drew researchers to investigate cognitive symptoms in patients with rheumatoid arthritis (RA). We discuss the prevalence and nature of patient-reported cognitive concerns, how these subjective complaints compare with objective neurocognitive testing, and what current studies reveal underlying inflammatory and neurobiological mechanisms. The conversation examines the cognitive effects of commonly used RA therapies, as well as modifiable contributors—including physical activity, sleep apnea, diet, and stress—that clinicians should assess in routine practice. We also consider when formal neuropsychological evaluation is warranted, how to counsel patients seeking to prevent cognitive decline, and the most pressing unanswered questions that remain in the field. 

In this episode, we explore what happens when clinicians look beyond the prescription pad and begin listening more deeply to what their patients have lost. This isn't a conversation about rejecting medications but about expanding the tools we use to foster healing. We discuss the concept of disenfranchised grief—the often-unspoken losses that accompany chronic illness—the intricate links between depression and inflammation, and the transformative power of helping patients heal in ways that no pill alone can achieve.  This episode was sponsored by Pfizer

In this episode, we shine a light on Calcium Pyrophosphate Deposition Disease (CPPD)—a condition that has been hiding in plain sight for decades. Despite being common, painful, and prevalent in clinics everywhere, CPPD has long been misdiagnosed, undertreated, and under-researched. Our guest has been working to change that by uncovering the genetic and molecular underpinnings of the disease and exploring new ways to improve patient outcomes. We discuss what's new and what's next for CPPD, why it may be the most common inflammatory arthritis after age 60, how it overlaps with rheumatoid arthritis and osteoarthritis, and what emerging studies of biologics are revealing about its biology and untapped therapeutic potential.  This episode was sponsored by Pfizer

In this episode, we explore RheumCode, a groundbreaking new initiative from the American College of Rheumatology (ACR) designed to build a common digital language for rheumatology. RheumCode aims to ensure that data means the same thing wherever it lives—whether in an EHR, a clinic, or a registry—enabling systems to seamlessly communicate and make better use of the medical information already being documented. We discussed how RheumCode began, the collaboration behind its development, and its potential to transform the way clinicians practice; researchers study disease, and patients experience their care.  This episode was sponsored by Pfizer  

Welcome to ACR Convergence 2025 in Chicago! Here, Dr. Hausmann delivers a quick update on what our podcasts will cover while the meeting is in session. Don't forget to tune in to ACR on Air and ACR Journals on Air each morning, starting this Saturday, to catch up on the latest in Rheumatology

In this week's episode, we dive into the ins and outs of the rheumatology musculoskeletal ultrasound certification process—what it takes to log 150 scans, meet CME requirements, and ultimately sit for the exam. We're joined by Dr. Liudmila Kastsianok, who shares her insights on how ultrasound is reshaping clinical practice, from enhancing diagnostic accuracy to opening new avenues in research. We also explore how incorporating ultrasound into routine care can deepen the physician-patient relationship and improve communication. Finally, Dr. Kastsianok offers her perspective on where the field is headed and why ultrasound is becoming an essential skill for the next generation of rheumatologists. 

In this episode, we preview ACR Convergence 2025 in Chicago this October with Dr. Greg Gardner, Chair of the Annual Meeting Planning Committee (AMPC). We'll explore key topics like emerging therapies, AI in rheumatology, and highlights such as the Practice Innovation Summit, Ultrasound Course, and Fellows In Training (FiT) Program. Dr. Gardner also discusses highlights such as, CAR T-cell therapies, new non-renal lupus guidelines, a Live Journals Club focused on Big Data and why this year's meeting is earlier on the calendar. Tune in for a sneak peek at what's to come! 

In recognition of Rheumatic Disease Awareness Month this September, this episode explores the critical yet often underutilized role of exercise in the management of rheumatic diseases. We examine how structured movement—ranging from step counts to resistance training—can significantly alter the trajectory of pain, function, and overall disease progression. Our discussion offers practical strategies for helping patients integrate physical activity into their daily routines, with a focus on starting gradually and maintaining consistency. We also address the heightened cardiovascular risks associated with rheumatoid arthritis and how targeted exercise interventions can mitigate these risks. Finally, we delve into fall prevention tactics and the use of technology and interdisciplinary care teams to set achievable, patient-centered goals that physical therapists can effectively support.   

It's been over two decades since the American College of Rheumatology (ACR) last released comprehensive treatment guidelines for systemic lupus erythematosus (SLE), and much has changed. In this episode, we're joined by Dr. Lisa Sammaritano to discuss the forthcoming 2025 ACR Guidelines for the Treatment of SLE. These updated recommendations reflect a significant evolution in our approach to lupus care, from the growing range of therapeutic options to a stronger emphasis on patient engagement and minimizing steroid toxicity. We'll dive into how the guidelines tailor treatment across diverse organ systems and patient populations, and what clinicians need to know to effectively incorporate these updates into their practice. 

In this episode, we're joined by Karen Durrant, founder of the Autoinflammatory Alliance, who shares her powerful journey from a determined parent seeking a diagnosis for her child to the leader of a global patient advocacy movement. What began as a personal quest has evolved into an international network supporting thousands affected by autoinflammatory diseases. Karen discusses how her collaboration with Dr. Fatma Dedeoglu, a leading pediatric rheumatologist, helped bridge the gap between patient experience and medical research—ultimately contributing to the development of international clinical guidelines that are transforming care for rare disease patients worldwide.  Autoinflammatory Alliance Systemic Autoinflammatory Disease (SAID) Support Autoinflammatory Alliance: Coparison Chart

In this episode, we're joined by myositis expert Dr. Brian Feldman to explore Juvenile Dermatomyositis (JDM). We cover its clinical presentation, key diagnostic clues, and the workup including labs and imaging. We examine the MDA5 variant, known triggers, and non-pharmacologic management strategies. Dr. Feldman also addresses the high-stakes scenario of JDM-associated rapidly progressive interstitial lung disease, offering insights into pathophysiology, imaging, and aggressive early treatment. The episode concludes with a look at the field's questions that remain. 

In this episode, we're joined by Dr. Dana DiRenzo to explore groundbreaking developments in the treatment of Sjögren's Disease. For the first time, therapies like BAFF blockade, CD40 ligand inhibitors, and FcRn antagonists appear poised to change the course of the disease—moving beyond symptom management to potential disease modification. We delve into the underlying science, current clinical trials, and tackle the big question: how early is early enough to begin treatment? Dr. DiRenzo also shares her expert perspective on holistic symptom management through what she calls the "4 Pillars of Health," offering practical strategies for improving quality of life for those living with Sjögren's. 

In this episode, we take the leap from the structured world of rheumatology fellowship into the dynamic, often unpredictable landscape of private practice. Dr. J. Thomas Berry shares his personal journey, offering an honest and insightful look at the transition. From the practical differences between academic and private settings to the business learning curve, patient care dynamics, and how he stays clinically sharp, this conversation is a must-listen for fellows preparing to enter independent practice 

In this episode, we examine Behcet's Disease—a rare, multisystem inflammatory disorder that continues to challenge traditional frameworks of autoimmunity and vasculitis. Dr. Johannes Nowatzky joins us to discuss the disease's hallmark features, including recurrent mucocutaneous ulcers and ocular involvement, as well as its geographic distribution and genetic associations. We explore the diagnostic difficulties posed by its heterogeneous presentation and symptom overlap with other conditions, and the rationale behind individualized, often multidisciplinary treatment strategies. This conversation offers valuable insights into a condition that remains as enigmatic as it is clinically significant. 

In this episode, we deliver a critical update on the rapidly evolving legislative landscape impacting rheumatology. We explore the intense policy battles shaping the future of the field, including steep Medicare reimbursement cuts threatening the survival of many practices. We also examine the ongoing challenges posed by pharmacy benefit managers (PBMs) and the growing uncertainty around research funding. Joining us is a special guest, Lennie Shewmaker McDaniel, JD, who brings a firsthand perspective from Capitol Hill, shedding light on what it truly takes to advocate for our patients and the profession in today's complex policy environment. 

In this episode, we examine the evaluation of pain in patients with chronic inflammatory arthritis, with particular attention to spondyloarthritis and its clinical overlap with fibromyalgia. We explore why some patients continue to report persistent pain despite well-controlled inflammation, and the importance of distinguishing between active inflammatory disease and centralized pain syndromes such as fibromyalgia. Join us as we unpack the diagnostic nuances that can significantly impact patient care. 

This episode explores the evolving role of GLP-1 agonists in rheumatology, highlighting their potential to influence weight, inflammation, and overall disease activity. Our guest expert unpacks how adipose tissue contributes to systemic inflammation and why managing body weight is crucial in the treatment of rheumatic diseases. We delve into the underlying science, real-world clinical applications, and the exciting future of incorporating GLP-1 therapies into comprehensive rheumatologic care—offering fresh insight into a therapeutic class with game-changing potential. 

In this episode, we dive into the evolving role of AI in rheumatology—exploring how it's already reshaping workflows, enhancing diagnostic accuracy, optimizing treatment selection, and helping us monitor patients remotely. We tackle big questions around bias, control over critical data and whether we're truly ready to let AI serve as our assistants—or even gatekeepers. From addressing workforce shortages to revolutionizing medical research and education, we examine both the promise and the pitfalls of this powerful technology, and why caution must guide its integration into our clinical decisions.

In this episode, we dive into the complexities of IgG4-Related Disease (IgG4-RD), a mysterious and multi-organ condition that continues to challenge both patients and physicians. Back in January 2024, Dr. John Stone introduced us to the emerging landscape of treatments for IgG4-RD, and today, Dr. Matthew Baker joins us to provide an exciting update. With new therapies on the horizon, we explore the role of B and T cell pathogenesis, the limitations of traditional steroid treatments, and the off-label use of rituximab. We also take a closer look at the promising results from the "Mitigate Trial," which offers hope for future strategies in managing this enigmatic disease. Join us as we discuss the evolving treatment landscape and what lies ahead for those affected by IgG4-RD. 

In this episode, we dive into a fascinating and often overlooked aspect of rheumatology: complications from diabetes that can mimic rheumatic diseases. Dr. Schiopu kicks off the discussion by shedding light on Diabetic Myonecrosis, a painful muscle condition that can be easily mistaken for other rheumatic disorders. We then explore Scleroderma, a skin-thickening muscle disorder that resembles systemic sclerosis (SSC) but has distinct underlying mechanisms. Dr. Schiopu shares invaluable insights on how to approach complex rheumatology consults in the hospital, emphasizing the importance of thoughtful diagnostic reasoning. She also discusses why sometimes the best approach in medicine is to avoid unnecessary tests and treatments, prioritizing patient care and accuracy in diagnosis.